buy

Regeneron Pharmaceuticals Inc. buy Guggenheim

Regeneron Pharmaceuticals Inc.

Start price

€530.00

/ 50%

Target price

01.05.26

Performance (%)

Price

Summary

This prediction is currently active. The prediction currently has a performance of . Dividends of are taken into consideration when calculating the performance. This prediction currently runs until 01.05.26. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Feedback

Performance without dividends (%)

Name	1w	1m
Regeneron Pharmaceuticals Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Guggenheim for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 716.364

Change

Ends at

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Guggenheim from $940.00 to $810.00. They now have a "buy" rating on the stock.

Ratings data for REGN provided by MarketBeat

Guggenheim